The pharmaceutical industry in India was valued at $50 billion in 2024 and is projected to touch $130 billion by 2030. India is the world’s largest supplier of generic drugs, contributing approximately 20% of global volume, and is also the global leader in vaccines, supplying nearly 60% of worldwide demand. These figures clearly highlight how critical the growth of this industry is to the nation’s economic and healthcare ecosystem.
Pharmaceutical manufacturing and storage facilities are highly energy-intensive. They operate under strict temperature control, energy efficiency, and regulatory compliance requirements, all of which are non-negotiable. Cleanrooms, cold-chain infrastructure, and production units must consistently maintain precise temperature and humidity levels to protect active pharmaceutical ingredients (APIs), vaccines, and finished drugs. Even minor temperature fluctuations can lead to regulatory deviations and manufacturing failures.
Traditional dark or conventional roofs absorb up to 90% of incoming solar radiation, turning these facilities into heat islands and forcing HVAC systems into overdrive—especially in hot climatic zones like India.
By applying LuminX, this challenge can be effectively reversed. Independent testing has demonstrated that LuminX Cool Roof coatings can reduce roof surface temperatures by 20–25°C on hot days compared to conventional roofs. This reduction in heat transfer directly results in lower cooling loads. Peer-reviewed studies show that energy savings of 15–30% are achievable in pharmaceutical facilities located in climatic zones 1–4, which includes India.
Moisture control is equally critical in pharmaceutical manufacturing, especially for certain chemical compounds. In some sensitive environments, even fans are prohibited as they can disrupt evaporation and condensation rates. In such scenarios—where low temperatures and stable humidity must be maintained without mechanical intervention—LuminX performs exceptionally well. Its coating technology helps prevent heat and moisture build-up, ensuring stable indoor conditions.
For temperature-critical zones such as stability chambers and cold storage warehouses (often operating below freezing), the benefits of LuminX Cool Roof are even more pronounced. One of our esteemed API manufacturing clients retrofitted 40,000 sq. ft. of roof area with LuminX and recorded a 20% reduction in refrigeration compressor runtime, along with improved temperature uniformity across the storage facility.
Beyond energy savings, LuminX significantly extends roof life by reducing thermal cycling and UV degradation. Most pharmaceutical plants operate under validated conditions, where unplanned roof replacements can trigger extensive documentation, audits, and production downtime. Enhanced roof durability therefore delivers both financial benefits and regulatory risk reduction.
With sustainability and ESG reporting becoming mandatory, pharmaceutical companies can now account for verified emission reductions achieved through LuminX under relevant ESG categories. Several global pharmaceutical leaders have already incorporated high-SRI roof coatings into their net-zero roadmaps.
In summary, LuminX delivers measurable and impactful benefits to the pharmaceutical sector, including:
15–20% energy savings, improved temperature stability, extended roof lifespan, reduced regulatory risk, and achievable decarbonisation goals.
For an industry that spends billions annually on energy and compliance, LuminX Cool Roof stands out as one of the simplest, fastest, and most cost-effective interventions available.